Decisions alongside fighting.
The Drug Basket 2024/ShutterStock
After a continuous marathon of discussions in recent weeks, mainly due to a two-month delay in the committee's meeting, due to the war, the Health Basket Committee announced today (Wednesday) which medicines, treatments and technologies will receive public funding starting in 2024.
The announcement of the Health Basket Committee was opened by the Minister of Health,
H. As Uriel Bosso
, who said: "Since Saturday, October 7, the Ministry of Health is facing a very complex reality - between emergency and routine.
Faced with this reality ,
the basket
committee set out and worked around the clock in order to come up with recommendations that manage to balance the complex needs with social sensitivity and human compassion.
" Medicines and technologies aimed at preventing diseases, but also many medicines that give health, relief from suffering and prolong life. For me, this is also a sad day for those patients for whom we were not able to generalize new technologies."
Over 110 medicines and technologies are included in the basket, including treatments for about 317 thousand people at a total cost of NIS 650 million.
Among them: a screening test for pregnant women for the entire population to detect genetic diseases, treatment for adults with attention disorders, an artificial pancreas for adults with type 1 diabetes, advanced treatments for cancer and kidney diseases, treatment for multiple sclerosis and many treatments for rare diseases that in previous years could not be answered.
These are the prominent drugs that have been approved:
For the full report with all the decisions of the basket committee for 2024 - click here
cancer
Famigatinib:
for effective second-line treatment for patients with cholangiocarcinoma, a rare and aggressive cancer of the biliary tract.
The health basket does have the test to detect the genomic change, which is responsible for the development of the disease, but there is no target-oriented treatment for this genomic change in the basket.
The treatment causes a delay in the proliferation of cancer cells.
Trudelvey:
an innovative biological treatment, the first to be approved for patients with triple-negative metastatic breast cancer.
The most aggressive type of metastatic breast cancer.
Edestris:
The drug was included this year for the treatment of Hodgkin lymphoma patients aged 18-60 whose disease is progressive, a disease that is mostly common among people aged 20-30.
The drug was in the health basket for first-line treatment only for adult patients over 60 whose disease is progressing.
Young patients whose disease was diagnosed in late stages are treated with very aggressive chemotherapy that can cause severe side effects such as suppression of the bone marrow, secondary malignancy and impaired fertility.
Extendi:
an oral medication intended for the treatment of men with prostate cancer, in various stages of the disease.
Jardians:
a drug that helps prevent the deterioration of renal function, in patients with chronic renal failure.
The drug has now been approved in the health basket for groups of kidney failure patients who so far have not received a medicinal response in the basket.
The drug is considered a game changer for these patients.
Linferase:
a drug for patients with prostate cancer with a mutation in the BRCA gene.
It was included in the drug basket this year after it demonstrated a 34% reduction in the risk of disease progression or death from it.
Prostate cancer is the most common malignant disease in men.
The treatment of the disease today is chemical castration through hormonal therapy that suppresses the secretion of the male sex hormone - testosterone.
However, about a third may develop resistance to the hormonal treatment, and are at risk of disease recurrence and the appearance of metastases.
Zosepta:
a life-prolonging drug for acute myeloid leukemia AML.
It is the only dedicated drug and the first one approved for the treatment of these seriously ill patients.
Extend the act
This is how you will improve performance and pleasure in bed - with an exclusive sale
in collaboration with "Gabra"
A wide variety of drugs for rare diseases.
The Drug Basket 2024/ShutterStock
rare diseases
Vaksogo:
One of the happy news this year that comes out of the basket committee, is the approval of a drug for a rare disease called achondroplasia, which prevents children from growing tall, to the point of defining dwarfism.
Until now, the treatment was difficult and painful surgery (patients with the disease defined this treatment as "a client from the time of the Inquisition").
A new drug that has already been successfully tested on a number of patients in Israel, was approved this year in Sel at a cost of over one million shekels per year per child.
The drug manages to double the growth rate of children suffering from this syndrome.
Kabalibi:
a medicine that contributes to a significant decrease in the damage caused by the disease TTP to important organs such as the brain, kidneys and heart and significantly reduces the rates of complications from the disease.
TTP is a rare autoimmune blood disease that attacks a specific protein in the body and radically disrupts the clotting mechanism.
This year the treatment was also extended to children.
Angiomo:
The drug is used to reduce the need for red blood cell transfusions due to hemolysis in adults with a rare disease called CAD.
This is a rare autoimmune hemolytic anemia, which develops when the patient's immune system attacks and destroys the red blood cells
Bilvi:
the first approved drug treatment, from the age of six months, for the treatment of Pfik disease (Pfic) progressive familial cholestasis, a rare liver disease that affects infants and children.
Istorisa:
for the treatment of endogenous Cushing's syndrome in adults who are not amenable to surgery or who have not been cured following the existing treatments in Sel.
The syndrome results from an excess of the hormone cortisol in the body, which is secreted from the adrenal gland and is responsible for maintaining blood pressure in the body, the activity of the immune system and metabolism.
This is a serious disease, which also affects the mental blocks of it.
The new treatment is considered a game changer in the field.
Litpolo:
intended for children and adults for alopecia areata, a common autoimmune inflammatory disease, in which the immune system attacks the hair follicles, causing hair loss and baldness throughout the body.
This is the first drug for the treatment of adults suffering from the disease that allows the regeneration of hair growth.
Viagra:
treatment for myasthenia gravis, an autoimmune disease characterized by severe muscle weakness that develops in young women (under 40) and men in their third years (over 60).
Offers an improvement in the motor skills of daily activities and reduces muscle weakness.
Alzonris:
for patients with the rarest leukemia called BPDCN, a violent disease whose incidence is 1 patient per 2.5 million people.
In Israel every year only about 4 people are diagnosed with the disease.
Sefazolimab:
generalized pustular psoriasis is a rare inflammatory skin disease, characterized by repeated acute flare-ups of pustules in the skin, and accompanied by systemic symptoms that can be life-threatening.
This is the first and only biological treatment that has been proven to be effective and safe in clinical studies and has been approved in the USA, Europe and Israel for this disease.
Dupixent:
for the treatment of a rare inflammation of the esophagus that causes choking on food. This is the only biological drug available to treat the rare disease that can deteriorate into a life-threatening condition.
diabetes mellitus
Artificial pancreas:
Starting this year, even adults suffering from type 1 diabetes will be able to receive an artificial pancreas, which will save them daily injections and punctures.
This is an automatic hybrid system for monitoring sugar and administering insulin in a customized way for ages 18-40.
Ozmpik:
We know it mainly because of its use for weight loss, it entered the basket this year, but with a label for diabetics only.
So far, the drug has been given in all health funds, except in general.
Now also members of Klalit, about half of the country's citizens, will be able to benefit from it.
The use of the drug for weight loss continues as usual, but self-financed and in the private market.
ADHD
Vivanes:
belongs to the group of stimulants of the central nervous system (brain) and is intended for the treatment of attention deficit disorder and reduces impulsivity and hyperactivity (ADHD).
The drug increases the levels of dopamine and norepinephrine (the neurotransmitters associated with learning, attention and behavior) and thus improves the ability to concentrate, maintain attention, learn, organize and reduce hyperactivity.
Vyance has also been found to be effective for moderate to severe compulsive eating disorders.
This year the coverage for her was also extended to 18-28 year olds, after it had already been approved for younger people in previous years.
Those that did not enter the basket
On the other hand, many medicines, technologies and treatments did not enter the basket this year.
The category that stands out in its absence this year from the medicine basket - vaccines.
Not a single vaccine entered the health basket this year.
For example, the
Bexaro
vaccine for the deadly meningococcal B bacteria in children, which almost entered last year, but was left behind at the last moment, was not approved this year either.
Another important vaccine, which surprisingly was not approved -
the RSV vaccine
, for infants and the elderly, a disease that causes the largest number of hospitalizations.
More on the same topic:
Health basket
Medicines